Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction

CompletedOBSERVATIONAL
Enrollment

652

Participants

Timeline

Start Date

January 13, 2019

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Heart Failure, Left SidedLeft Ventricular DysfunctionVentricular Remodeling
Interventions
DIAGNOSTIC_TEST

Role of Sacubitril/Valsartan in Hemodynamic and Echocardiographic Improvement of Heart Failure With Reduced Ejection Fraction

Reverse Remodeling is Associated With Hemodynamic Improvement and Stabilization in Outpatients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan: an Echocardiographic Study

Trial Locations (1)

56124

Frank Lloyd Dini, Pisa

All Listed Sponsors
collaborator

Università degli Studi di Brescia

OTHER

collaborator

Federico II University

OTHER

collaborator

Ospedali Riuniti di Foggia

OTHER

collaborator

University Of Perugia

OTHER

collaborator

Monaldi Hospital

OTHER

collaborator

University of Messina

OTHER

collaborator

University of Siena

OTHER

collaborator

University of Salerno

OTHER

collaborator

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

collaborator

Azienda Ospedaliero-Universitaria di Parma

OTHER

collaborator

Azienda Unita Sanitaria Locale di Piacenza

OTHER

lead

Italian Society of Cardiology

OTHER

NCT04397302 - Role of Sacubitril/Valsartan in the Improvement of Heart Failure With Reduced Ejection Fraction | Biotech Hunter | Biotech Hunter